How Do CGRPs Work? Key and Lock Analogy

During the 60th Annual American Headache Society (AHS) Scientific Conference in San Francisco, I had the distinct pleasure of sitting down with Dr. David Dodick, professor of neurology and a headache specialist at the Mayo Clinic in Phoenix, Arizona. In part one of this interview, Dr. Dodick discussed the importance of setting realistic expectations on how this new treatment – CGRPs, may reduce migraine frequency. In part two of our discussion, Dr. Dodick explains how CGRP antibodies function like a key and a lock and how future forms of this medication are also promising.

The good news and the bad news

Dr. Dodick candidly explains, “The bad news is you have maybe a 1 in 5 chance of not responding in the right way… The good news is there’s more coming.” Based on his key and lock analogy, there’s hope for those who try the new treatment but may not respond to the “lock antibodies” as they may respond to the “key antibodies” that are developed in the future.

Join the discussion

Want to know how others living with migraine are doing with this new treatment? Check out the discussion in the forums section of the Migraine.com community or ask a question in the Q&A section.

This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The Migraine.com team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.

Comments

View Comments (2)

Poll